{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:38:12Z","timestamp":1784191092849,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Vaccines and Diagnostics Inc."},{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.vaccine.2018.12.059","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T19:33:18Z","timestamp":1548531198000},"page":"1209-1218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-3863","authenticated-orcid":false,"given":"Terry","family":"Nolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Santolaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinandus","family":"de Looze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Henein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Heaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten P.","family":"Perrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartley","family":"Garfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murdo","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"O'Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.12.059_b0005","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.059_b0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2018.12.059_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2051013616681365","article-title":"Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States","volume":"5","author":"Banzhoff","year":"2017","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.vaccine.2018.12.059_b0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5694\/mja16.01340","article-title":"Epidemiology of invasive meningococcal B disease in Australia, 1999\u20132015: priority populations for vaccination","volume":"207","author":"Archer","year":"2017","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2018.12.059_b0025","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of Serogroup B meningococcal disease in one region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.059_b0030","doi-asserted-by":"crossref","first-page":"e44102","DOI":"10.1371\/journal.pone.0044102","article-title":"Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006\u20132010","volume":"7","author":"Ibarz-Pavon","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.12.059_b0035","unstructured":"Australian Government. Department of Health. Invasive meningococcal disease national surveillance report with a focus on MenW. 31 December 2017; 2017."},{"key":"10.1016\/j.vaccine.2018.12.059_b0040","unstructured":"Pan-Canadian Public Health Network Partners in Public Health. 2014. The Recommended Use of the Multicomponent Meningococcal B (4CMenB) Vaccine in Canada. Available from: <https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/recommended-use-multicomponent-meningococcal-b-4cmenb-vaccine-canada.html> [accessed 2017 Aug 30]."},{"key":"10.1016\/j.vaccine.2018.12.059_b0045","series-title":"Departamento de Epidemiolog\u00eda","author":"de Salud","year":"2015"},{"key":"10.1016\/j.vaccine.2018.12.059_b0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.12.059_b0055","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.12.059_b0060","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.12.059_b0065","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/14760584.2015.979799","article-title":"Evolving meningococcal immunization strategies","volume":"14","author":"Safadi","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.12.059_b0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","article-title":"Routinely vaccinating adolescents against meningococcus: targeting transmission & disease","volume":"15","author":"Vetter","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.12.059_b0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/2047773214Y.0000000126","article-title":"Global practices of meningococcal vaccine use and impact on invasive disease","volume":"108","author":"Ali","year":"2014","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.vaccine.2018.12.059_b0080","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.12.059_b0085","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1016\/j.vaccine.2015.06.103","article-title":"Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study","volume":"33","author":"Perrett","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.059_b0090","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.12.059_b0095","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.12.059_b0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.vaccine.2016.11.071","volume":"35","author":"Read","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.059_b0105","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/j.vaccine.2015.06.011","article-title":"Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults","volume":"33","author":"Nolan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.059_b0110","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.12.059_b0115","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jinf.2017.12.005","article-title":"Antibody persistence and booster responses 24\u201336 months after different 4CMenB vaccination schedules in infants and children: a randomised trial","volume":"76","author":"Martinon-Torres","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2018.12.059_b0120","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/CVI.05028-11","article-title":"Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis","volume":"18","author":"Mak","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.12.059_b0125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0264-410X(96)00161-2","article-title":"Factors associated with superior antibody responses to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age","volume":"15","author":"Levine","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.059_b0130","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.059_b0135","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","article-title":"Serum bactericidal antibody assays - the role of complement in infection and immunity","volume":"33","author":"McIntosh","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.059_b0140","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.059_b0145","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2017.05.023","article-title":"Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial","volume":"35","author":"Martinon-Torres","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19300283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19300283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:30:11Z","timestamp":1759401011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19300283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0264410X19300283"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}